Milestone Pharmaceuticals Inc
NASDAQ:MIST
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Milestone Pharmaceuticals Inc
Depreciation & Amortization
Milestone Pharmaceuticals Inc
Depreciation & Amortization Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Depreciation & Amortization | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Milestone Pharmaceuticals Inc
NASDAQ:MIST
|
Depreciation & Amortization
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Depreciation & Amortization
-$1B
|
CAGR 3-Years
6%
|
CAGR 5-Years
9%
|
CAGR 10-Years
8%
|
|
|
Canopy Growth Corp
TSX:WEED
|
Depreciation & Amortization
-CA$21.4m
|
CAGR 3-Years
24%
|
CAGR 5-Years
25%
|
CAGR 10-Years
-30%
|
|
|
Cronos Group Inc
TSX:CRON
|
Depreciation & Amortization
-$2.1m
|
CAGR 3-Years
29%
|
CAGR 5-Years
6%
|
CAGR 10-Years
-37%
|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Depreciation & Amortization
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Depreciation & Amortization
-CA$49.5m
|
CAGR 3-Years
1%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-86%
|
|
Milestone Pharmaceuticals Inc
Glance View
Milestone Pharmaceuticals, Inc. engages in the development and commercialization of cardiovascular medicines. The company is headquartered in Montreal, Quebec and currently employs 29 full-time employees. The company went IPO on 2019-05-09. The firm is focused on the development and commercialization of cardiovascular medicines. Milestone’s lead product candidate is etripamil. The etripamil is a novel, potent and short-acting calcium channel blocker that has been designed rapid-onset nasal spray, which is self-administered by patients. The firm is developing etripamil to treat paroxysmal supraventricular tachycardia (PSVT), atrial fibrillation (AF) and rapid ventricular rate, and other cardiovascular indications.
